Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells

Journal of Immunotherapy

Volumn 28, Issue 4, 2005, Pages 332-342

  Dauer, Marc ^a   Herten, Jan ^a   Bauer, Christian ^a   Renner, Frederik ^a   Schad, Katharina ^a   Schnurr, Max ^a   Endres, Stefan ^a   Eigler, Andreas ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Chemotherapy; Cyclooxygenase 2 inhibitors; Dendritic cells; Immunotherapy; Pancreatic carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CD3 ANTIGEN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; FAS ANTIBODY; FAS ANTIGEN; GEMCITABINE; HLA A2 ANTIGEN; LIGAND; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; TUMOR ANTIGEN;

APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CARCINOMA CELL; CELL KILLING; CELL LYSATE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG MECHANISM; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; MOLECULAR INTERACTION; MONOCYTE; PANCREAS CARCINOMA; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VACCINATION;

EID: 21844463061     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000164038.41104.f5     Document Type: Article

References (44)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics 2003. CA Cancer J Clin. 2003;53:5-26.
2. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet. 1997;349: 485-489.
3. Brand RE, Tempero MA. Pancreatic cancer. Curr Opin Oncol. 1998;10: 362-366.
4. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15: 2403-2413.
5. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811.
6. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4: 328-332.
7. Schuler-Thurner B, Dieckmann D, Keikavoussi P, et al. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol. 2000;165:3492-3496.
8. Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA. 2001;98:8809-8814.
9. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 2001;61:6451-6458.
10. Zinkernagel RM. Immunity against solid tumors? Int J Cancer. 2001;93: 1-5.
11. Tong Y, Song W, Crystal RG. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res. 2001;61:7530-7535.
12. Tanaka F, Yamaguchi H, Ohta M, et al. Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo. Int J Cancer. 2002;101:265-269.
13. Shin JY, Lee SK, Kang CD, et al. Antitumor effect of intratumoral administration of dendritic cell combination with vincristine chemotherapy in a murine fibrosarcoma model. Histol Histopathol. 2003;18:435-447.
14. Albert ML, Pearce SF, Francisco LM, et al. Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med. 1998;188:1359-1368.
15. Belz GT, Carbone FR, Heath WR. Cross-presentation of antigens by dendritic cells. Crit Rev Immunol. 2002;22:439-448.
16. Schnurr M, Scholz C, Rothenfusser S, et al. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and γδ T cells. Cancer Res. 2002;62:2347-2352.
17. Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol. 2003; 170:4905-4913.
18. Correale P, Aquino A, Giuliani A, et al. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int J Cancer. 2003;104:437-445.
19. Bergmann-Leitner ES, Abrams SI. Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunol Immunother. 2001;50:445-455.
20. Bergmann-Leitner ES, Abrams SI. Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL. J Immunol. 2000;164:4941-4954.
21. Grover JK, Yadav S, Vats V, et al. Cyclo-oxygenase 2 inhibitors: emerging roles in the gut. Int J Colorectal Dis. 2003;18:279-291.
22. Pockaj BA, Basu GD, Pathangey LB, et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol. 2004;11:328-339.
23. Elder DJ, Halton DE, Hague A, et al. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res. 1997;3:1679-1683.
24. Piazza GA, Rahm AK, Finn TS, et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 1997;57:2452-2459.
25. Eibl G, Reber HA, Wente MN, et al. The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas. 2003;26:33-41.
26. Totzke G, Schulze-Osthoff K, Janicke RU. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene. 2003;22:8021-8030.
27. DeLong P, Tanaka T, Kruklitis R, et al. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res. 2003; 63:7845-7852.
28. Zeytin HE, Patel AC, Rogers CJ, et al. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA. Tg/MIN mice. Cancer Res. 2004;64:3668-3678.
29. Schnurr M, Galambos P, Scholz C, et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res. 2001; 61:6445-6450.
30. Valmori D, Fonteneau JF, Lizana CM, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol. 1998;160:1750-1758.
31. Dauer M, Obermaier B, Herten J, et al. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol. 2003;170:4069-4076.
32. Kalyuzhny A, Stark S. A simple method to reduce the background and improve well-to-well reproducibility of staining in ELISPOT assays. J Immunol Methods. 2001;257:93-97.
33. Dauer M, Pohl K, Obermaier B, et al. Interferon-alpha disables dendritic cell precursors: dendritic cells derived from interferon-alpha-treated monocytes are defective in maturation and T-cell stimulation. Immunology. 2003;110:38-47.
34. Grunewald R, Kantarjian H, Du M, et al. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol. 1992;10:406-413.
35. Grosch S, Tegeder I, Niederberger E, et al. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 2001;15:2742-2744.
36. Kobie JJ, Wu RS, Kurt RA, et al. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res. 2003;63:1860-1864.
37. Arlt A, Gehrz A, Muerkoster S, et al. Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 2003;22:3243-3251.
38. Li Y, Singh B, Ali N, et al. Induction of growth inhibition and apoptosis in pancreatic cancer cells by auristatin-PE and gemcitabine. Int J Mol Med. 1999;3:647-653.
39. Yip-Schneider MT, Sweeney CJ, Jung SH, et al. Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001;298:976-985.
40. Molina MA, Sitja-Arnau M, Lemoine MG, et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999;59:4356-4362.
41. Ding XZ, Tong WG, Adrian TE. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res. 2000;20:2625-2631.
42. Tseng WW, Deganutti A, Chen MN, et al. Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. J Gastrointest Surg. 2002;6:838-843.
43. Phillips RK, Wallace MH, Lynch PM, et al. A randomised, double-blind, placebo-controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002;50:857-860.
44. Nzeako UC, Guicciardi ME, Yoon JH, et al. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology. 2002;35: 552-559.